all-cis-5,8,11,14,17-icosapentaenoic acid

Term ID

CHEBI:28364

Synonyms

(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
(all-Z)-5,8,11,14,17-eicosapentaenoic acid
5,8,11,14,17-EICOSAPENTAENOIC ACID
5,8,11,14,17-Icosapentaenoic acid
all-cis-5,8,11,14,17-eicosapentaenoic acid
all-cis-icosa-5,8,11,14,17-pentaenoic acid
cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid
cis-5,8,11,14,17-eicosapentaenoic acid
cis-5,8,11,14,17-EPA
cis-Delta(5,8,11,14,17)-eicosapentaenoic acid
Eicosapentaenoic acid
EPA
icosapent
Icosapentaenoic acid
icosapento
icosapentum
Timnodonic acid

Definition

An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.

References

Beilstein:1714433
CAS:10417-94-4
DrugBank:DB00159
Drug_Central:3174
HMDB:HMDB0001999
KEGG:C06428
KEGG:D08061
KNApSAcK:C00000408
KNApSAcK:C00001215
LIPID_MAPS_instance:LMFA01030759
MetaCyc:EICOSAPENTAENOATE
PDBeChem:EPA
PMID:12549599
PMID:18638380
PMID:19054597
PMID:21118482
PMID:21274596
PMID:23920312
PMID:24108131
PMID:24238887
PMID:24387137
PMID:24389665
PMID:9668087
Reaxys:1714433

Ontology

ChEBI ( EBI )

Relationships

is a type of: icosapentaenoic acid omega-3 fatty acid

icosapentaenoic acid omega-3 fatty acid Show first 5 Terms
has_role: anticholesteremic drug antidepressant antineoplastic agent Daphnia galeata metabolite fungal metabolite ... Show All 8 Terms

anticholesteremic drug antidepressant antineoplastic agent Daphnia galeata metabolite fungal metabolite micronutrient mouse metabolite nutraceutical Show first 5 Terms
inverse has_functional_parent: (5Z,8Z,11Z,14Z,16E,18R)-18-hydroperoxyicosapentaenoic acid (5Z,8Z,11Z,14Z,17Z)-icosapentaenoyl-containing glycerolipid (5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine (5Z,8Z,11Z,17Z)-14,15-epoxyicosatetraenoic acid (5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoic acid ... Show All 25 Terms

(5Z,8Z,11Z,14Z,16E,18R)-18-hydroperoxyicosapentaenoic acid (5Z,8Z,11Z,14Z,17Z)-icosapentaenoyl-containing glycerolipid (5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine (5Z,8Z,11Z,17Z)-14,15-epoxyicosatetraenoic acid (5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoic acid (5Z,9E,11Z,14Z,17Z)-8-hydroperoxyicosapentaenoic acid (5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoic acid (6E,8Z,11Z,14Z,17Z)-5-oxoicosapentaenoic acid 1-[(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl]-2-[(9Z)-octadecenoyl]-sn-glycero-3-phosphocholine 1-[(9Z)-octadecenoyl]-2-[(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl]-sn-glycero-3-phosphocholine 1-[(11Z)-octadecenoyl]-2-[(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl]-sn-glycero-3-phosphocholine 1-hexadecanoyl-2-[(5Z,8Z,11Z,14Z,17Z)-icosapentaenoyl]-sn-glycero-3-phosphocholine 1-hexadecyl-2-[(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl]-sn-glycero-3-phosphocholine 1-icosanoyl-2-[(5Z,8Z,11ZZ,14Z,17Z)-eicosapentaenoyl]-sn-glycerol 1-octadecanoyl-2-[(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl]-sn-glycero-3-phosphocholine 2-[(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl]-sn-glycerol 5,20-diHEPE 11-HEPE 12-HPEPE 17(18)-EpETE 19-HEPE 20-HEPE cholesteryl (5Z,8Z,11Z,14Z,17Z-eicosapentaenoate) ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate timnodonoyl bioconjugate Show first 5 Terms
inverse is_conjugate_base_of: all-cis-5,8,11,14,17-icosapentaenoate

all-cis-5,8,11,14,17-icosapentaenoate Show first 5 Terms
inverse is_substituent_group_from: (5Z,8Z,11Z,14Z,17Z)-icosapentaenoyl group

(5Z,8Z,11Z,14Z,17Z)-icosapentaenoyl group Show first 5 Terms
is_conjugate_acid_of: all-cis-5,8,11,14,17-icosapentaenoate

all-cis-5,8,11,14,17-icosapentaenoate Show first 5 Terms

Phenotype

Phenotype resulting from all-cis-5,8,11,14,17-icosapentaenoic acid

Phenotype where environments contain all-cis-5,8,11,14,17-icosapentaenoic acid

Phenotype modified by environments containing all-cis-5,8,11,14,17-icosapentaenoic acid

Human Disease Model